Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.71 |
| ▸ | CA4 | P22748 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ECE1 | P42892 | 3/20 | 0.41 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ENO1 | P06733 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7747522 | 0.94 | CA2 (0.74) | CA2CA4MEN1KMT2AECE1 | |
| Sparfosic Acid SCHEMBL3514530 | 0.83 | CA2 (1.00) | CA2CA4MEN1KMT2ACA1 | |
| Pala SCHEMBL59449 | 0.83 | CA2 (1.00) | CA2CA4MEN1KMT2ACA1 | |
| Pala SCHEMBL859680 | 0.82 | CA2 (0.96) | CA2CA4MEN1KMT2ACA1 | |
| Pala SCHEMBL31389020 | 0.82 | CA2 (0.96) | CA2CA4MEN1KMT2ACA1 | |
| Sparfosic Acid SCHEMBL31237824 | 0.82 | CA2 (0.96) | CA2CA4MEN1KMT2ACA1 | |
| Pala SCHEMBL11121904 | 0.82 | CA2 (0.96) | CA2CA4MEN1KMT2ACA1 | |
| SCHEMBL30052291 | 0.79 | ECE1 (0.50) | CA2CA4MEN1KMT2AECE1 | |
| SCHEMBL16401 | 0.79 | ECE1 (0.50) | CA2CA4MEN1KMT2AECE1 | |
| SCHEMBL7184807 | 0.79 | ECE1 (0.50) | CA2CA4MEN1KMT2AECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078082-A1 | Methods and compositions to treat glycosaminoglycan-associated molecular interactions | HPSE, CD44, CSGALNACT1 | CA2 1005/4885CA4 509/4885MEN1 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.